Products in Development

At INSYS, we're focused on developing and commercializing innovative drugs and novel drug delivery systems that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products.

Our product pipeline is concentrated on developing medicines that directly address areas of unmet medical needs, including pain, opioid dependence, reversal of opioid-induced respiratory depression, prevention of nausea and vomiting, and ovarian and gastric cancer.

In addition, our pipeline is purposed to address the significant unmet needs of severe pediatric epilepsies such as Dravet Syndrome, infantile spasms, and Lennox-Gastaut Syndrome.

 

Compound Area of Research Status
Dronabinol Oral Solution Nausea / Vomiting Associated with Cancer Chemotherapy and Anorexia / Weight Loss in Patients with AIDS
Buprenorphine Sublingual Spray Moderate to Severe Pain
Naloxone Sublingual Spray Reversal of Opioid Depression
Cannabidiol Severe Pediatric Epilepsies
Buprenorphine Naloxone Sublingual Spray Opioid Dependence
Ondansetron Sublingual Spray Prevention of Nausea and Vomiting
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Cervical and Cholangiocarcinoma

COMPOUND

Approved Products

As a premier provider and manufacturer of innovative drugs and novel drug delivery systems, we aim to set new standards with our progressive line of products.

 

Approved Products

As a premier provider and manufacturer of innovative drugs and novel drug delivery systems, we aim to set new standards with our progressive line of products.